Doja Pak helped popularize Permanent Marker, contributed to the rise of Zoap and RS11, and spent years building one of the most respected names in California cannabis culture. Now it is moving into the regulated European medical market — and it has a specific complaint about what it is finding there.
The brand, founded by Ryan Bartholomew and rooted in Northern California’s cannabis heritage, has announced a partnership with CP Medical to enter Germany and the United Kingdom through exclusive arrangements with Bloomwell and Mamedica respectively. The first products to reach German patients are Doja Z and Doja Permanent Marker. The UK launch follows closely, adding CP Z and CP Super Lemon Haze to the lineup.
Doja Z marks the first introduction of the multi-award-winning Z genetic into Germany’s medical sector. Doja has served as custodian of the original breeder cut for over seven years. Permanent Marker — named Leafly’s 2023 Strain of the Year and originally commercialized by Doja Exclusives — brings one of the most recognizable cultivars in recent cannabis history into a fully regulated pharmaceutical framework for the first time.
The quality problem they’re trying to solve
The partnership is built around a pointed critique of the European medical cannabis market as it currently operates. According to CP Medical, compliance has become the endpoint rather than the starting point — and the gap between regulatory approval and actual product quality is significant.
The specific issues they identify: genetics selected for ease of cultivation rather than consumer experience, seed selections passed off under commercial strain names with no meaningful connection to original genetics, and a near-total absence of legacy cultivation expertise in production decisions. The result, they argue, is compliant cannabis that lacks the terpene depth, genetic authenticity and experiential quality that long-term consumers recognize.
One of their more …
Read More
Author: Javier Hasse / High Times
